6 terminated, 3 recruiting, 2 completed, 1 not yet recruiting. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 5, Recruiting 3 |
| Phase 2 | 5 | Completed 2, Terminated 2, Not yet recruiting 1 |
Follow Aurigene Discovery Technologies Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study) AUR103 Calcium - Neuroendocrine (NE) Tumors, Advanced NET of GI Origin | Phase 2 | Not yet recruiting | Aurigene Discovery Technologies Limited | 30 | 2026-06-30 | 2026-06-11 |
| A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma AUR103 Calcium, Trastuzumab + CAPOX (Capecitabine + Oxaliplatin) - HER 2 Positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Aurigene Discovery Technologies Limited | 2 | 2025-03-22 | 2026-04-17 |
| Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma AUR112 - Relapsed Advanced Lymphomas | Phase 1 | Recruiting | Aurigene Discovery Technologies Limited | 40 | 2025-01-15 | 2026-01-13 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) AUR104 - Select Relapsed/Refractory Lymphoid Malignancies | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 9 | 2024-12-12 | 2026-04-17 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers AUR109 200mg, AUR109 300mg, AUR109 400mg - Ovarian Cancer, Colorectal Cancer | Phase 2 | Terminated | Aurigene Discovery Technologies Limited | 29 | 2024-11-09 | 2026-04-17 |
| A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) AUR108 - Relapsed Advanced Lymphomas | Phase 1 | Recruiting | Aurigene Discovery Technologies Limited | 40 | 2023-10-19 | 2026-04-17 |
| A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) AUR107 - Relapsed Malignant Solid Neoplasm | Phase 1 | Recruiting | Aurigene Discovery Technologies Limited | 50 | 2023-09-05 | 2026-04-17 |
| A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies AUR106 - Relapse, Advanced Malignant Neoplasm | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 21 | 2023-08-26 | 2026-04-17 |
| First in Human, Dose Escalation, Dose Expansion Study of AUR105 AUR105 - Solid Tumor, Adult, Non-hodgkin Lymphoma | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 17 | 2022-11-30 | 2026-04-17 |
| A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics AUR103 - Solid Tumor, Adult, Acute Myeloid Leukemia | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 27 | 2022-09-16 | 2026-04-17 |
| A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) AUR101, Placebo - Plaque Psoriasis | Phase 2 | Completed | Aurigene Discovery Technologies Limited | 141 | 2021-05-04 | 2022-12-13 |
| A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis AUR101, Matching Placebo - Chronic Plaque-type Psoriasis | Phase 2 | Completed | Aurigene Discovery Technologies Limited | 90 | 2020-01-21 | 2023-08-14 |
Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Kidney Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Esophageal Neoplasms (2) · Psoriasis (2) · Recurrence (2) · Stomach Neoplasms (2) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
Capecitabine (1) · Oxaliplatin (1) · Trastuzumab (1)
India (10) · United States (2)
Akhil Kumar (4) · Akhil Kumar, MD (2) · Divyesh Mandavia, MD (1) · Shilendra Pandey, MSc (1)